UPCC 16517: A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer
Enrolling By Invitation
99 years or below
All
Phase
1
10 participants needed
1 Location
Brief description of study
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: ['Non-Small-Cell Lung Cancer']
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 828637
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
